Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Double-Blind Phase 1b/2 Combined Staggered Multiple Dose Escalation Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care

NCT03371251 is registered in ClinicalTrials.gov with Boston Pharmaceuticals as lead sponsor.

NCT NCT03371251
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03371251 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Double-Blind Phase 1b/2 Combined Staggered Multiple Dose Escalation Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care
Lead sponsor
Boston Pharmaceuticals
Phase
Phase 1/2
Overall status
Completed
Start date
January 10, 2018
Completion date
November 26, 2020
Enrollment
143 (actual)
Sites
68

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus